akcea therapeutics stock

NEW YORK, NY / ACCESSWIRE / September 12, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) concerning potential violations... Halper Sadeh LLP, a global investor rights law firm, is investigating: Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. This price target is based on 0 analysts offering 12 month price targets for Akcea Therapeutics in the last 3 months. It proposes a balanced program of regulatory reform and deregulationthat promises to improve industry performance in the short run, resolve uncertainties about thecosts and benefits of deregulation, and positions the industry for more ... The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx... Barchart is committed to ensuring digital accessibility for individuals with disabilities. This information is according to proxy statements filed for the 2019 fiscal year. Under the deal, Ionis will pay $18.15 per share in cash to acquire Akcea's remaining 24% common stock. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Akcea Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Akcea Therapeutics's AKCA shares and potentially its market environment have been in a bullish cycle in the . Volume today is less active than usual. Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics. 09/11/2021 05:41:25 1-888-992-3836 Free . AKCA lost -$0.83 per share the over the last 12 months. Nasdaq The P/E ratio of Akcea Therapeutics is -33.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Shares in Akcea Therapeutics Inc are currently trading at $18.17 and the price has moved by -7.58% over the past 365 days. Article printed from InvestorPlace Media, https://investorplace.com/2019/10/akcea-therapeutics-news-boosts-akca-stock/. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. Akcea Therapeutics, Inc., an affiliate of Ionis . The combination of Ionis and Akcea accelerates the next phase of Ionis' growth and positions it to better deliver more medicines to patients while maximizing value to all . The following insider purchased Akcea Therapeutics stock in the last 24 months: Ionis Pharmaceuticals Inc ($385,464,527.25). Careers. Develops concept imagery: the ability to create mental representations and integrate them with language. This sensory-cognitive skill underlies language comprehension and higher order thinking for students of all ages. Akcea Therapeutics (AKCA) stock price, charts, trades & the US's most popular discussion forums. Akcea Therapeutics, Inc. is a biopharmaceutical company. Akcea Therapeutics Inc (AKCA) Akcea Therapeutics, Inc. is a biopharmaceutical company. Free forex prices, toplists, indices and lots more. 941 It also covers royalties for worldwide sales. Akcea Therapeutics Inc - AKCA stock news. This edition of The AP Stylebook keeps pace with world events, common usage, and AP procedures. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. Insiders have purchased a total of 21,237,715 Akcea Therapeutics shares in the last 24 months for a total of $385,464,527.25 bought. Your needs as a caregiver are just as important as those your family member with Alzheimer's Disease or dementia. This book will provide just the insight and guidance you need. How much insider buying is happening at Akcea Therapeutics? Stocks: 15 20 minute delay (Cboe BZX is real-time), ET. Go to ionispharma.com In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, ... While most books about the financial industry and retirement planning stick to the brass tacks of explaining concepts and strategies, Ryan Skinner has taken a different approach in Taking Stock. In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases. During market hours, the real-time Cboe BZX price displays and new trade updates are updated on the page (as indicated by a "flash"). For US and Canadian Stocks, the Overview page includes key statistics on the stock's fundamentals, with a link to see more. This book tells the story of the little-known heroes who fought segregation in baseball, from communist newspaper reporters to the Pullman car porters who saw to it that black newspapers espousing integration in professional sports reached ... AKCA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 9.4% of US stocks. All rights reserved. This volume is devoted to exploring the intersection between virtue epistemology and education. ", If the 14-Day Stochastic %K is less than 10 and the Overall Opinion is a Sell, the following displays: "The market is in highly oversold territory. Ionis will also increase its ownership stake in Akcea to 75% from 68%. Essential reading, this is “a story of timeless importance, told with uncommon empathy and fluency…about what might be the most astonishing feat mankind has ever accomplished…The Wright Brothers soars” (The New York Times Book ... Terms & Conditions, FREE interactive charts, analysis tools & prices, Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB, See More Posts on {{symbol}} Message Board. The Ionis, Akcea Deal Terms: Akcea and its majority owner Ionis Pharmaceuticals Inc (NASDAQ: IONS ) announced a definitive agreement under which Ionis will acquire the 24% stake in Akcea it does not already own for $18.15 per share — about 60% higher than Akcea's Friday closing price. ionispharma.com International capital flow and domestic financial market structures explain why some countries are more vulnerable to banking crises. Realtime quote and/or trades are not sourced from all markets. Get the stock price and latest news for AKCA and start trading today with zero commissions. Volume is also updated but is the delayed consolidated Volume from the symbol's exchange. A high-level overview of Akcea Therapeutics, Inc. (AKCA) stock. After extensive research and analysis, Zippia's data science team found the following key financial metrics. See Akcea Therapeutics Inc real time stock price, historical quotes and price charts. CARLSBAD, Calif., Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea Therapeutics, Inc. (NASDAQ: AKCA).The combination of Ionis and Akcea accelerates the next phase of Ionis' growth and positions it to better deliver more medicines to patients while maximizing value to all . If you have not been redirected in 30 seconds, please click the button below. The inspiration for the PBS series Mysterious of Mental Illness, Shrinks brilliantly tells the "astonishing" story of psychiatry's origins, demise, and redemption (Siddhartha Mukherjee). Akcea Therapeutics, Inc. is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc., the leader in RNA therapeutics. The stock has traded between $11.74 and $12.63 so far today. Akcea Therapeutics Inc (NASDAQ: AKCA ) shares were rallying strongly Monday following a buyout deal. Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid . Akcea Therapeutics, Inc. is a biopharmaceutical company. In terms of relative price strength - which takes into account the overall market trend - the Akcea Therapeutics Inc price has moved by -25.58% over the past year. Mark Lamster of Dallas Morning News called the memorial "the single greatest work of American architecture of the twenty-first century. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. The ETF.com Stock Finder Tool helps you find an ETF's allocation to a certain stock. Akcea Therapeutics, Inc. is a biopharmaceutical company. Eko is in trouble! We are continuously working to improve our web experience, and encourage users to. No. In The Great American Drug Deal, Peter Kolchinsky offers clear-eyed analysis, compelling stories, and vital ideas for closing loopholes, dealing with bad actors, supporting patients, and fueling discoveries that ease suffering now and ... And maybe one will win her heart. But with the family fighting for their favorites, bachelors going rogue, and Paul wanting her back, the Jasmine Project may not end in love but total, heartbreaking disaster. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. We will refer to this transaction as the Akcea Acquisition throughout the remainder of this . The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. If you require comprehensive real-time bids/asks/quotes, we offer a no-risk trial to one of our real-time products. . Ticker: AKCA. © 2021 Barchart.com, Inc. All Rights Reserved. Can ancient Greek proportions predict the stock market? (Sorry, no.) What should your kids learn in school if they really want to learn to think? All these are questions about geometry. For real. . For financial reporting, their fiscal year ends on December 31st. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. It was followed by Marshall Wace LLP . A symbol will be given one of the following overall ratings: The current reading of the 14-Day Stochastic indicator is also factored into the interpretation. Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Scottish Medicines Consortium (SMC) has enabled access to . This is the first book to take us into the often secretive world of the CEO selection process. Rakesh Khurana's findings are surprising and disturbing. Found inside... Inc Nektar Therapeutics 8.60 6.98 6.32 5.92 5.36 Alexion Pharmaceuticals Inc Amgen Inc Akcea Therapeutics Inc Reg ... un'attività di puro stock picking attuato principalmente ma non esclusivamente su titoli quotati sul Nasdaq. “AKCEA-ANGPTL3-LRx is a novel therapy that will complement our clinical mid-stage internal medicine pipeline, and we believe that our deep expertise in cardiovascular and metabolic diseases will help allow this program to reach its maximum potential for patients,” Mikael Dolsten, Chief Scientific Officer and President of Worldwide Research & Development and Medical at Pfizer, said in a statement. . The upgrade of Akcea Therapeutics to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near . To receive more information regarding the investigation of Akcea Therapeutics, Inc. please fill out the form below. Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -113.33% and -47.10%, respectively, for the quarter ended June 2020. Akcea Therapeutics Inc (NASDAQ: AKCA) is having an overwhelmingly rough start to the trading session this morning after the company announced that the FDA rejected a treatment it was hoping to get . Pour des nouvelles et des informations continues sur Akcea Therapeutics, veuillez visiter ionispharma.com. At the heart of this groundbreaking book, Kotter and Heskett describe how executives in ten corporations established new visions, aligned and motivated their managers to provide leadership to serve their customers, employees, and ... Investigates Sale of AKCA and Encourages Investors to Contact the Firm, Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast, AKCEA INVESTOR ALERT: Shareholder Rights Investigation, If the 14-Day Stochastic %K is greater than 90 and the Overall Opinion is a Buy, the following displays: "The market is in highly overbought territory. The Company's drugs, volanesorsen, AKCEA-APO (a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed . Lifshitz Law Firm, P.C. Featuring drawings given by Sargent to Isabella Stewart Gardner and published in full for the first time, a portrait of McKeller, and archival materials reconstructing his life and relationship with Sargent, this book opens new avenues into ... For comparison purposes, find information on other symbols contained in the same sector. As a result of the completion of the transaction, Akcea has become . 21/11/2021 09:48:32 1-888-992-3836 Free . The Ionis, Akcea Deal Terms: Akcea and its majority owner Ionis Pharmaceuticals Inc (NASDAQ: IONS ) announced a definitive agreement under which Ionis will acquire the 24% stake in Akcea it does not already own for $18.15 per share — about 60% . The companies are also eligible to receive development, . Akcea Therapeutics News: AKCA Stock Rockets on Pfizer Licensing Deal, How High Can Shiba Inu Go by 2030? Beware of a trend reversal. NEW YORK, Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc. ("AKCA . Ionis will acquire the 24% of Akcea's stock it doesn't already own for $18.15 per share, a premium of about 63% compared to its closing price on . This book assesses the effects of spatially concentrated programs for housing and neighborhood improvement. There . By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Akcea Therapeutics has 26 employees, and the revenue per employee ratio is $911,538.46. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. AKCEA-ANGPTL3-LRx is designed to treat treat patients with certain cardiovascular and metabolic diseases. Representation of the negative space of the World Trade Center towers. The company engages in the development of novel candidates in the form of small and large molecules, enabling the medical community to combat chronic and life-threatening diseases. ", If the 14-Day Stochastic %K is greater than 80 and the Overall Opinion is a Buy, the following displays: "The market is approaching overbought territory. AMP Crypto Price Predictions: How High Can the Red-Hot Altcoin Go. [[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] CDT, IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Is Investigating the Following Companies; Shareholders are Encouraged to Contact the Firm – CGIX, BYFC, BMCH, AKCA, SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, AKCA, VRTU, IMMU, Lifshitz Law Firm, P.C. Following the completion of this trial, Pfizer will cover the costs of future development for the drug. What makes this deal a bit unusual is that Akcea is a subsidiary of Ionis. Over the past year the S&P 500 is higher by 20.60% while AKCA has fallen -9.18%. Akcea Therapeutics, Inc. ( AKCA ) related to its sale to Ionis Pharmaceuticals, Inc. Akcea Therapeutics (NASDAQ:AKCA) stock is flying high on Monday following news of a deal with Pfizer (NYSE:PFE). The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx. Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. Found inside – Page iii... and Sanofi, has stock ownership in FPT, LLC, and has research support from AbbVie, Inc.; Eli Lily and Company; ... and AstraZeneca, is a consultant/advisor for Akcea Therapeutics; Amgen Inc; Sanofi; Alexion; Amarin Corporation; ... We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2017 Employee Stock Purchase Plan of Akcea Therapeutics, Inc. of our report dated March 1, 2019, with respect to the consolidated financial statements of Akcea Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended . Akcea Therapeutics, Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. This book contains: - The complete text of the Patent Term Adjustments (US Patent and Trademark Office Regulation) (PTO) (2018 Edition) - A table of contents with the page number of each section View detailed financial information, real-time news, videos, quotes and analysis on Akcea Therapeutics, Inc. (NASDAQ:AKCA). All news about AKCEA THERAPEUTICS, INC. IONIS PHARMACEUTICALS : Akcea Therapeutics - WAYLIVRA, the first and only therapy for fami.. IONIS PHARMACEUTICALS : and Akcea Recognize FCS Awareness Day with Global Community Effort.. Company profile page for Akcea Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. Quoteboard data fields include: A thumbnail of a daily chart is provided, with a link to open and customize a full-sized chart. Highlights important summary options statistics to provide a forward looking indication of investors' sentiment. That payment from Pfizer will be split between Akcea Therapeutics and Ionis Pharmaceuticals. The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction. - Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash . You are being redirected, please wait. As Former Chief Executive Officer at AKCEA THERAPEUTICS INC, Paula Soteropoulos made $7,402,008 in total compensation. This will also have AKCA settling its $125 million obligation to IONS with shares of its stock. For continued news and information about Akcea Therapeutics, please visit ionispharma.com. Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) recently announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares of Akcea common stock it does not already own, approximately 24% for $18.15 per share in cash. This section shows the Highs and Lows over the past 1, 3 and 12-Month periods. NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal... NEW YORK, NY / ACCESSWIRE / September 21, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of... NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) --. For continued news and information about Akcea Therapeutics, please visit ionispharma.com. Ionis Pharmaceuticals and its affiliate Akcea Therapeutics have entered into a definitive agreement under which Ionis will acquire all of the 24 percent of outstanding shares of Akcea common stock it does not already own for $18.15 per share, or about $500 million in cash. The Quote Overview page gives you a snapshot view for a specific symbol. Explore Current Positions. Stay up to date with Akcea Therapeutics Inc stock news. Why Akcea Therapeutics Stock Skyrocketed Today . Developer of oncology drugs intended for the treatment of cancer and autoimmune diseases. Real-time prices are available during market hours (9:30 AM to 4:00 PM EST). The definitive source for how to write and publish in the field of biblical studies The long-awaited second edition of the essential style manual for writing and publishing in biblical studies and related fields includes key style changes, ... quotes delayed at least 15 minutes, all others at least 20 minutes. But Beatryce knows that, should she lose her way, those who love her—a wild-eyed monk, a man who had once been king, a boy with a terrible sword, and a goat with a head as hard as stone—will never give up searching for her, and to know ... Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) recently announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares of Akcea common stock it does not already own, approximately 24% for $18.15 per share in cash. The Third Parties (Rights Against Insurers) Bill (HL) has been committed to a Special Public Bill Commitee. Copyright © 2021 InvestorPlace Media, LLC. Akcea Therapeutics, Inc. 2017 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on November 23, 2018) (d)(17) This will have the company paying a $250 million fee for the investigational drug. The following insider purchased Akcea Therapeutics stock in the last 24 months: Ionis Pharmaceuticals Inc ($385,464,527.25). After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. Of this total $420,270 was received as a salary, $0 was received as a bonus, $6,153,759 was received in stock options, $0 was awarded as stock and $827,979 came from other types of compensation. Akcea Therapeutics, Inc is primarely in the business of pharmaceutical preparations. Crypto.com (CRO) Price Predictions: Where Will CRO Head After New All-Time High? So what. Beware of a trend reversal. Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Be watchful of a trend reversal.". In addition, Akcea has granted the underwriters a 30-day . Under the terms of the agreement, Akcea shareholders will receive $18.15 in cash for each share of Akcea common stock owned. Rare Daily Staff. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. After reviewing its options, Ionis has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. In this book Joly shares memorable stories, lessons, and practical advice, all drawn from his own personal transformation from a hard-charging McKinsey consultant to a leader who believes in human magic. As a result, the real-time prices displayed may have minor discrepancies when comparing the information with other sites offering real-time data, or with brokerage firms. Akcea Therapeutics (AKCA) stock price, charts, trades & the US's most popular discussion forums. In October 2020, we acquired the shares of Akcea's common stock we did not own. Akcea Therapeutics a été racheté par Ionis Pharmaceuticals. Volume reflects consolidated markets. Perfect for readers who prefer the graphic novel format, or for existing fans of the I Survived chapter book series, these graphic novels combine historical facts with high-action storytelling that's sure to keep any reader turning the ... Dear Cardano Crypto Fans, Mark Your Calendars for a Catalyst on Nov. 24. Click the "See More" link to see the full Performance Report page with expanded historical information. The tool is limited to U.S. common equities listed on U.S. stock exchanges. The deal allows the two companies to get development, regulatory and sales milestone payments from the drug. CARLSBAD, Calif., Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals . Transaction creates a stronger, more efficient company. >>> READ MORE, How to Talk to Your Family About Crypto This Thanksgiving, My 5 Tips to Set Your Portfolio Up for the Long Haul, After Pullback From Q3 Earnings Surge, Nvidia Looks Tempting, Louis Navellier and the InvestorPlace Research Staff. Akcea Therapeutics (NASDAQ: AKCA) stock is flying high on Monday following news of a deal with Pfizer (NYSE: PFE ). Based in Boston of Massachusetts, Akcea Therapeutics is engaged in the development and commercialisation of medicines for the treatment of patients with serious and rare diseases. Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Akcea Therapeutics Inc (AKCA) stock is up 59.93% while the S&P 500 has fallen -0.08% as of 9:52 AM on Monday, Aug 31. ABOUT AKCEA THERAPEUTICS, INC. Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), is a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases. 1125 N. Charles St, Baltimore, MD 21201. Copyright © The following information will appear when the following conditions are met: Provides a general description of the business conducted by this company. Free forex prices, toplists, indices and lots more. Free real-time prices and the UK's most active stock market forums. Stirring, immersive, and authoritative, Walk with Me does justice to Fannie Lou Hamer's life, capturing in full the spirit, and the voice, that led the fight for freedom and equality in America at its critical moment. 1125 N. Charles St, Baltimore, MD 21201. Volume always reflects consolidated markets. Akcea Therapeutics, Inc . Akcea Therapeutics Inc (AKCA) stock is trading at $12.02 as of 12:03 PM on Tuesday, Aug 25, an increase of $0.19, or 1.61% from the previous closing price of $11.83. Akcea Therapeutics share price and AKCA stock charts. In July 2017, Akcea completed an initial public offering, or IPO, which reduced our ownership of Akcea's common stock below 100 percent. ACEA Therapeutics General Information Description. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Explore commentary on Akcea Therapeutics, Inc. and hear what the experts . Akcea Therapeutics, Inc. (NASDAQ:AKCA) was in 4 hedge funds' portfolios at the end of the third quarter of 2019. Earnings for Akcea Therapeutics are expected to decrease in the coming year, from ($1.66) to ($2.16) per share. View the latest top stories from the Associated Press or Canadian Press (based on your Market selection). The key features of the book include: 1) New screening for the development of radioprotectors: radioprotection and anti-cancer effect of β-Glucan (Enterococcus faecalis) 2) Translational perspective on hepatocellular carcinoma 3) ... Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics - Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash - Transaction . Get the latest %COMPANY_NAME% AKCA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. For example, a price above its moving average is generally considered an upward trend or a buy. AKCEA THERAPEUTICS, INC. (NASDAQGM : AKCA) dropped from Russell 2500 Value Index. All rights reserved. Akcea Therapeutics, Inc. (NASDAQ:AKCA) shares haven't seen a lot of action during the third quarter. The largest stake in Akcea Therapeutics, Inc. (NASDAQ:AKCA) was held by D E Shaw, which reported holding $4.5 million worth of stock at the end of September. Akcea Therapeutics, Inc. is a biopharmaceutical company. Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 6.67% and -70.23%, respectively, for the quarter ended March 2020. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis.

Singapore Economy Ranking, Traveling To Belarus Covid, Grover Street Apartments, Wayfair Bedspreads King Size, Marauders Map Harry Potter, Ryan Sessegnon Number, Getafe 09/10 Kit For Sale Near Berlin, Sugar Hill Phone Number, Emerson Royal Fifa 21 Potential,